A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome)

Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Male and female patients aged =18 years
•2.Patients who have been prescribed Saroglitazar for NAFLD will be included in this Phase 4 study (patients who use Saroglitazar for the first time)
•3.Patients able to and willing to provide written informed consent and comply with the requirements of the study protocol
•4.Patients with a prior documented diagnosis of NAFLD based on the AASLD criteria (Refer Appendix III for diagnostic criteria). NAFLD is defined either by previous histology or clinical imaging in individuals who consume little or no alcohol and do not have a cause for secondary hepatic steatosis or another cause of chronic liver disease. In addition, patients must have one of the following criteria to indicate ongoing NAFLD at screening:
•a.Liver stiffness through transient elastography, an LSM =8 kPa
•b.Serum ALT =45 U/

•1.Consumption of alcohol for at least 90 consecutive days in last one year: >2 units of alcohol per day ( >14 units per week) for males and >1 unit of alcohol per day ( >7 units per week) for females.
•2.History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and haemochromatosis.
•3.Patient has known documented cirrhosis, either based on clinical criteria or liver histology or imaging.
•4.Contraindications to Saroglitazar or any disease conditions affecting the ability to evaluate the effects of Saroglitazar.
•5.History or other evidences of severe illness or any other conditions that would make patient, in the opinion of the investigator, unsuitable for the study.
•6.Any previous history of ascites, hepatic encephalopathy, oesophageal varices or admission/emergency department visit for hepatic decompensation.
•7. Women of child bearing potential: inability or unwillingness to practice contraception for the duration of the study.
•8. Pregnant or breast feeding females.

发起方

Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)